{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T12:48:30Z","timestamp":1785674910601,"version":"3.56.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare, autosomal-dominant (AD) multisystem disorder resulting from the extracellular deposition of amyloid fibrils formed by a destabilized mutant form of transthyretin (TTR), a transport protein predominantly produced by the liver.<\/jats:p><jats:sec><jats:title>Aim<\/jats:title><jats:p>The aims of the current study are to demonstrate the Bulgarian experience with the screening programs among the high-risk patient population over the last 7 years, to present the results from the therapy with TTR stabilizer in our cohort, as well as to stress on the importance of a follow-up of asymptomatic carriers with TTR pathogenic variants by a multidisciplinary team of specialists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>In 2014, a screening program among the high-risk patient population for ATTRv was initiated in Bulgaria. On one hand, it was conducted to identify new patients and families among people with \u201cred flag\u201d clinical features, while on the other hand, the program aimed to identify TTR mutation carriers among the families with already genetically proven diagnoses. Sanger sequencing methodology was used to make fast target testing for mutations in the <jats:italic>TTR<\/jats:italic> gene in the suspected individuals. All of the identified carriers underwent subsequent evaluation for neurological, cardiac, gastroenterological, and neuro-ophthalmological involvement. Those considered affected were provided with multidisciplinary treatment and a follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As a result of a 7-year selective screening program among the high-risk patient population and relatives of genetically verified affected individuals, 340 carriers of TTR mutations were identified in Bulgaria with the following gene defects: 78.53% with Glu89Gln, 10.29% with Val30Met, 8.24% with Ser77Phe, 2.06% with Gly47Glu, and 0.59% with Ser52Pro. All of these affected displayed a mixed phenotype with variable ages at onset and rate of progression, according to their mutation. From the 150 patients treated with TTR stabilizer, 84 remained stable, while in other 66 patients the treatment was terminated either because of polyneuropathy progression or due to death. A program for a regular follow-up of asymptomatic carriers in the last 3 years enabled us to detect the transition of 39\/65 to symptomatic patients and to initiate treatment in a timely manner.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Bulgarian ATTRv patients display a mixed phenotype with some clinical peculiarities for each mutation that should be considered when treating the affected and the follow-up of the asymptomatic carriers of a specific gene defect.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.844595","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T07:22:49Z","timestamp":1649402569000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria"],"prefix":"10.3389","volume":"13","author":[{"given":"Teodora","family":"Chamova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Gospodinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ognian","family":"Asenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihomir","family":"Todorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zornitsa","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Kirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Cherninkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kastreva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Taneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislava","family":"Blagoeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sashka","family":"Zhelyazkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plamen","family":"Antimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaloian","family":"Chobanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albena","family":"Todorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivailo","family":"Tournev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"Benson","year":"2007","journal-title":"Muscle Nerve."},{"key":"B3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1136\/jmg.2003.014803","article-title":"Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy","volume":"41","author":"Ohmori","year":"2004","journal-title":"J Med Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst."},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/JND-180371","article-title":"Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis","volume":"6","author":"Kapoor","year":"2019","journal-title":"J Neuromuscul Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.2459\/JCM.0000000000001036","article-title":"Tournev I. Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of pGlu89Gln mutation","volume":"21","author":"Gospodinova","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.15386\/mpr-2218","article-title":"Screening for hereditary transthyretin amyloidosis in Bulgaria","volume":"94","author":"Nakov","year":"2021","journal-title":"Med Pharm Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13506129.2021.1935230","article-title":"Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria","volume":"28","author":"Pavlova","year":"2021","journal-title":"Amyloid"},{"key":"B11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13506129.2019.1634539","article-title":"Founder effect of the Glu89Gln TTR mutation in the Bulgarian population","volume":"26","author":"Kirov","year":"2019","journal-title":"Amyloid."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e19509","DOI":"10.1097\/MD.0000000000019509","article-title":"Fecal calprotectin levels are elevated in transthyretin amyloidosis patients with gastrointestinal manifestations","volume":"99","author":"Nakov","year":"2020","journal-title":"Medicine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1212\/WNL.45.6.1115","article-title":"Variables influencing neuropathic endpoints: the rochester diabetic neuropathy study of healthy subjects","volume":"45","author":"Dyck","year":"1995","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","article-title":"Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years","volume":"7","author":"Yamamoto","year":"2007","journal-title":"Am J Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/ene.13774","article-title":"Assessment of autonomic innervation of the foot in familial amyloid polyneuropathy","volume":"26","author":"Zouari","year":"2019","journal-title":"Eur J Neurol."},{"key":"B16","first-page":"115","article-title":"Cardiac autonomic involvement and peripheral nerve function in patients with diabetic neuropathy","volume":"12","author":"Spitzer","year":"1997","journal-title":"Funct Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/ejechocard\/jen174","article-title":"European association of echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies","volume":"9","author":"Evangelista","year":"2008","journal-title":"Eur J Echocardiogr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"American society of echocardiography's nomenclature and standards committee; task force on chamber quantification. Recommendations for chamber quantification","volume":"7","author":"Lang","year":"2006","journal-title":"Eur J Echocardiogr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovascular Imaging."},{"key":"B21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.15403\/jgld-422","article-title":"Transthyretin amyloidosis with gastrointestinal manifestation: a case report","volume":"28","author":"Nakov","year":"2019","journal-title":"J Gastrointestin Liver Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid."},{"key":"B23","unstructured":"SarafovS\n          Medical University of Sofia, Sofia, BulgariaClinico-Genetic and Epidemiologic Research in Hereditary Amyotrophic Lateral Sclerosis and Transthyretin Amyloidosis in Bulgaria2021"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/13506129.2011.565524","article-title":"Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis","volume":"18","author":"Koike","year":"2011","journal-title":"Amyloid."},{"key":"B26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1530\/ey.17.14.3","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature."},{"key":"B27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/humu.1380010306","article-title":"Two transthyretin variants (TTR Ala-49 and TTR Gln-89) in two Sicilian kindreds with hereditary amyloidosis","volume":"1","author":"Almeida","year":"1992","journal-title":"Hum Mutat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40119-021-00226-6","article-title":"Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic Loci: update from THAOS","volume":"10","author":"Gentile","year":"2021","journal-title":"Cardiol Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve."},{"key":"B30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid."},{"key":"B31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Plant\u00e9-Bordeneuve","year":"2007","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/13506120410001682578","article-title":"Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families","volume":"11","author":"Haagsma","year":"2004","journal-title":"Amyloid."},{"key":"B33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.nmd.2016.04.013","article-title":"Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey","volume":"26","author":"Durmu\u015f-Tek\u00e7e","year":"2016","journal-title":"Neuromuscul Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506120600877136","article-title":"Phenotypic and genotypic heterogenicity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies?","volume":"13","author":"Rapezzi","year":"2006","journal-title":"Amyloid."},{"key":"B35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12864-017-3646-1","article-title":"Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis","volume":"18","author":"Iorio","year":"2017","journal-title":"BMC Genomics."},{"key":"B36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/13506129.2013.844689","article-title":"Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes","volume":"20","author":"Polimanti","year":"2013","journal-title":"Amyloid."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1007\/s12035-017-0593-4","article-title":"Trans-acting factor may modify age at onset in familial amyloid polyneuropathy ATTRV30M in Portugal","volume":"55","author":"Alves-Ferreira","year":"2018","journal-title":"Mol Neurobiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.gene.2019.04.030","article-title":"Monoallelic expression of the TTR gene as a contributor to the age at onset and penetrance of TTR-related amyloidosis","volume":"705","author":"Yordanova","year":"2019","journal-title":"Gene."},{"key":"B39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/hmg\/ddi051","article-title":"Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease","volume":"14","author":"Soares","year":"2005","journal-title":"Hum Mol Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/bjo.81.4.295","article-title":"Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up","volume":"81","author":"Ando","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/13506129.2012.710669","article-title":"Vitreous surgery impact in glaucoma development in liver transplanted familial amyloidosis ATTR V30M Portuguese patients","volume":"19","author":"Beira~o","year":"2012","journal-title":"Amyloid."},{"key":"B42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","article-title":"Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases","volume":"22","author":"Beira~o","year":"2015","journal-title":"Amyloid."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IOP.0000000000002061","article-title":"Clinical and radiological features of intramuscular orbital amyloidosis: a case series and literature review","volume":"20","author":"Tong","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.844595\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T07:23:03Z","timestamp":1649402583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.844595\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":43,"alternative-id":["10.3389\/fneur.2022.844595"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.844595","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"article-number":"844595"}}